Spots Global Cancer Trial Database for postneoadjuvant therapy stage iv gastric cancer ajcc v8

Every month we try and update this database with for postneoadjuvant therapy stage iv gastric cancer ajcc v8 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events	NCT05038254	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Colo... Metastatic Esop... Metastatic Gast... Metastatic Live... Metastatic Mali... Metastatic Mali... Metastatic Mali... Metastatic Panc... Metastatic Rect... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Stage IV Colon ... Stage IV Hepato... Stage IV Pancre... Stage IV Rectal... Stage IV Small ... Stage IVA Colon... Stage IVA Hepat... Stage IVA Recta... Stage IVB Colon... Stage IVB Hepat... Stage IVB Recta... Stage IVC Colon... Stage IVC Recta...	Best Practice Patient Monitor... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Intravital Microscopy in Human Solid Tumors	NCT03823144	Solid Tumor, Ad... Clinical Stage ... Gastric Carcino... Malignant Solid... Metastatic Colo... Metastatic Gast... Metastatic Prim... Metastatic Sarc... Postneoadjuvant... Resectable Colo... Resectable Live... Resectable Panc... Resectable Sarc... Stage IV Colore...	Diagnostic Micr... Fluorescein Sod...	18 Years -	Mayo Clinic
Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma	NCT03395847	Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Gastroesophagea... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Unresectable Ga...	Pembrolizumab	18 Years -	M.D. Anderson Cancer Center
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer	NCT04329494	Clinical Stage ... Clinical Stage ... Clinical Stage ... Malignant Uteri... Metastatic Appe... Metastatic Colo... Metastatic Gast... Metastatic Mali... Metastatic Mali... Metastatic Ovar... Pathologic Stag... Peritoneal Carc... Postneoadjuvant... Stage IV Append... Stage IV Colore... Stage IV Ovaria... Stage IV Uterin... Stage IVA Appen... Stage IVA Color... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Appen... Stage IVB Color... Stage IVB Ovari... Stage IVB Uteri... Stage IVC Appen... Stage IVC Color...	Biopsy Cisplatin Doxorubicin Fluorouracil Intraperitoneal... Irinotecan Leucovorin Mitomycin Oxaliplatin Quality-of-Life... Questionnaire A...	18 Years -	City of Hope Medical Center
Intravital Microscopy in Human Solid Tumors	NCT03823144	Solid Tumor, Ad... Clinical Stage ... Gastric Carcino... Malignant Solid... Metastatic Colo... Metastatic Gast... Metastatic Prim... Metastatic Sarc... Postneoadjuvant... Resectable Colo... Resectable Live... Resectable Panc... Resectable Sarc... Stage IV Colore...	Diagnostic Micr... Fluorescein Sod...	18 Years -	Mayo Clinic
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers	NCT04221893	Stage IV Esopha... Stage IV Esopha... Stage IV Gastri... Stage IV Adenoc... Stage IVA Esoph... Stage IVA Esoph... Stage IVA Gastr... Stage IVA Adeno... Stage IVB Esoph... Stage IVB Esoph... Stage IVB Gastr... Stage IVB Gastr... Metastatic Anal... Metastatic Colo... Metastatic Esop... Metastatic Gast... Metastatic Gast... Metastatic Hepa... Metastatic Mali... Metastatic Smal... Pancreatobiliar... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Stage IV Anal C... Stage IV Colore... Stage IV Hepato... Stage IVA Color... Stage IVA Hepat... Stage IVB Color... Stage IVB Hepat... Stage IVC Color...	Radiation Thera...	18 Years -	University of California, San Francisco
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma	NCT05041153	Advanced Gastri... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Gast... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Unresectable Ga... Unresectable Ga...	Lenvatinib Pembrolizumab	18 Years -	M.D. Anderson Cancer Center
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer	NCT04220827	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Gast... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Peritoneal Carc... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant...	Paclitaxel	18 Years -	M.D. Anderson Cancer Center
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer	NCT03918499	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Gast... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Recurrent Gastr... Recurrent Gastr...	Cyclophosphamid... Cytokine-based ... Pembrolizumab	18 Years -	City of Hope Medical Center
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer	NCT04660760	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant...	Paclitaxel Quality-of-Life... Ramucirumab Trifluridine an...	18 Years -	Academic and Community Cancer Research United

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: